Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05836272
Other study ID # Tunisian ICUs association
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date August 1, 2023
Est. completion date December 2024

Study information

Verified date August 2023
Source Tunis University
Contact Ahlem Trifi
Phone 98692699
Email trifiahlem2@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The management of septic states includes, in addition to the specific treatment (antimicrobials and eradication of the source), a restoration of the hemodynamic disorders and assistance of the failing organs. In general, the restoration of hemodynamic disorders begins first with volume expansion, followed by the use of Noepinephrine (NE) when the target mean arterial pressure (MAP) is not reached after optimizing the intravascular volume. Recently, several studies have supported the interest of early NE on MAP, cardiac output and mortality. It is therefore tempting to restrict fluid administration even in the initial phase of hemodynamic management of severe sepsis by starting NE earlier.


Description:

Sepsis is characterized by systemic inflammation induced by a severe infection resulting in an inappropriate host response against that infection. On the microcirculatory scale, vasoplegia with capillary leakage is distinguished. Management of sepsis includes, in addition to specific treatment which includes antimicrobials and eradication of the source, restoration of hemodynamic disorders and assistance to failing organs. In general, the restoration of hemodynamic disorders begins first with volume expansion, followed by the use of vasopressors (mainly norepinephrine: NE as first-line therapy) when the mean arterial pressure target (MAP: reflecting the perfusion pressure organs) is not reached after optimizing the intravascular volume. Recently, several studies have supported the benefit of administering NE at the start of resuscitation of sepsis. Indeed, its administration at an earlier phase than usually recommended improved MAP and cardiac output with a favorable effect on mortality. At a median interval of 1.3 hours from ICU admission and exclusive administration of NE, MAP was adequately restored within a relatively short time (30 min) and was associated with a better survival rate than that predicted by the severity scores of similar patients from other series reported in the literature. In the recent Thai "CENSER" trial, shock was controlled in 76% of patients in the early NE group versus 48% (p<0.001). On the other hand, the administration of a large quantity of fluids inevitably increases the risk of fluid overload, which is a frequent complication in septic patients. In front of all these arguments, it is therefore tempting to restrict fluid administration even to the initial phase of the hemodynamic management of sepsis by starting NE earlier.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date December 2024
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age 18 or older. - The patient or his/her legal representative has given informed consent in writing. - Diagnosis of sepsis according to the definitions updated by the consensus of sepsis 3. - Mean arterial pressure < 65 mmHg Exclusion Criteria: - Diagnosis of septic shock prior to randomization (where NA requirements exceed those of the trial protocol) - Pregnancy, - Need for immediate surgery, - Neoplasia at an advanced stage - Circumstances where water restriction is the rule: - Acute pulmonary edema - Acute coronary syndrome,

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Norepinephrine Bitartrate
The NE will be prepared as follows: 4 mg mixed with 250 ml of 5% glucose resulting in a final norepinephrine concentration of 0.016 mg/ml. For the control group placebo: 250 ml of 5% glucose will be prepared. Both drugs will be infused via a peripheral line or a venous catheter. The intravenous infusion rate varies from 8 to 15 ml/hour, adjusted according to body weight to obtain norepinephrine at 0.05 microgram/kg/min (ie 0.128 to 0.24 mg per hour) in continuous infusion.
Other:
Placebo
For the control group placebo: 250 ml of 5% glucose will be prepared and will be infused via a peripheral line or a venous catheter. The intravenous infusion rate varies from 8 to 15 ml/hour.

Locations

Country Name City State
Tunisia intensive care unit of the University Hospital Center La Rabta Tunis

Sponsors (1)

Lead Sponsor Collaborator
Tunis University

Country where clinical trial is conducted

Tunisia, 

References & Publications (1)

Permpikul C, Tongyoo S, Viarasilpa T, Trainarongsakul T, Chakorn T, Udompanturak S. Early Use of Norepinephrine in Septic Shock Resuscitation (CENSER). A Randomized Trial. Am J Respir Crit Care Med. 2019 May 1;199(9):1097-1105. doi: 10.1164/rccm.201806-1034OC. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Use of invasive ventilation Use of invasive ventilation 48 hours
Other Variation of cardiac output Variation of Cardiac output assessed xith transthoracic cardiac ultrasound (the 15% threshold is considered to define an increase in CO). Within 6 hours
Primary shock control shock control is defined by a composite criterion (MAP > 65 mm Hg for 2 consecutive measurements and urinary output > 0.5 ml/kg/h for 2 consecutive hours) within 6 hours
Secondary Decrease in serum lactate Decrease in serum lactate > 10% from baseline within 6 hours
Secondary Volume of fluid Quantity of intravenous fluid received within 48 hours
Secondary Mortality Mortality 28 days
See also
  Status Clinical Trial Phase
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Recruiting NCT04796636 - High-dose Intravenous Vitamin C in Patients With Septic Shock Phase 1
Terminated NCT04134624 - EMS Prehospital Blood Culture Collection and Antibiotic Administration: A Two-Phase Pilot Project to Reduce Mortality in Patients With Severe Sepsis and Septic Shock N/A
Withdrawn NCT04821414 - Effects of IL-1β and Its Receptor Antagonists in the Treatment of Severe Infection and Inflammatory Storm in Children
Recruiting NCT05357339 - Microcirculation Properties of Albumin for Fluid Resuscitation in Septic Shock N/A
Recruiting NCT06178822 - Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room
Completed NCT04833621 - Is NMES Treatment in Sepsis/ Septic Shock Patients Protective in Development of ICU-AW? N/A
Not yet recruiting NCT04105400 - Procalcitonin in Diagnosis of Sepsis in Critically Ill Patient
Completed NCT04459572 - As an Early Indicator Biomarker of Prognosis and Mortality in Children With Sepsis and Septic Shock: suPAR N/A
Completed NCT04508296 - The Effect pf Goal-directed De-escalation in ARDS on Organ Function and Mortality N/A
Recruiting NCT03685214 - Comparison of Balanced Crystalloids and Normal Saline in Septic Patients N/A
Not yet recruiting NCT04850456 - Treatment Strategy of Human Gamma Globulin on the Therapy for Intensively Ill Children With Inflammatory Storm
Completed NCT04747795 - Early Administration of Vitamin C in Patients With Sepsis or Septic Shock in Emergency Departments Phase 3
Terminated NCT03821038 - Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis Patients Phase 2
Completed NCT05246969 - Detecting Sepsis in Patients With Severe Subarachnoideal Hemorrhage
Recruiting NCT05442710 - Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy Phase 2
Completed NCT05467605 - Effect of Probiotics on Cytokines in Sepsis in Children N/A
Completed NCT03974386 - Effects of Endotoxin Absorption and Cytokine Removal Hemofilter on Severe Septic Shock N/A
Recruiting NCT04203979 - Sepsis: From Syndrome to Personalized Care
Not yet recruiting NCT03367026 - Reducing Elevated Heart Rate in Patients With Severe Sepsis by Ivabradine N/A